DCM
CYTK icon

Driehaus Capital Management’s Cytokinetics CYTK Stock Holding History

Driehaus Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-220,384
Closed -$18.4M – 400
2023
Q4 		$18.4M Buy
+220,384
New +$7.98M 0.22% 144
2023
Q2 		– Sell
-365,348
Closed -$12.9M – 407
2023
Q1 		$12.9M Sell
365,348
-1,009
-0.3% -$41.2K 0.18% 184
2022
Q4 		$16.8M Sell
366,357
-1,239,957
-77% -$53.4M 0.25% 136
2022
Q3 		$77.8M Sell
1,606,314
-41,340
-3% -$1.99M 1.18% 11
2022
Q2 		$64.7M Sell
1,647,654
-239,509
-13% -$9.64M 1.05% 12
2022
Q1 		$69.5M Sell
1,887,163
-439,949
-19% -$15.6M 0.85% 17
2021
Q4 		$106M Sell
2,327,112
-562,414
-19% -$21.7M 1.08% 15
2021
Q3 		$103M Sell
2,889,526
-210,131
-7% -$6.19M 1.22% 6
2021
Q2 		$61.3M Sell
3,099,657
-135,981
-4% -$3.19M 0.81% 21
2021
Q1 		$75.3M Buy
3,235,638
+9,071
+0.3% +$194K 1.11% 12
2020
Q4 		$67M Buy
3,226,567
+194,869
+6% +$3.56M 1.08% 12
2020
Q3 		$65.6M Sell
3,031,698
-77,674
-2% -$1.82M 1.35% 9
2020
Q2 		$73.3M Buy
3,109,372
+135,770
+5% +$2.55M 1.78% 3
2020
Q1 		$35.1M Sell
2,973,602
-65,654
-2% -$838K 1.17% 13
2019
Q4 		$32.2M Buy
3,039,256
+319,091
+12% +$3.28M 0.86% 19
2019
Q3 		$31M Buy
2,720,165
+532,551
+24% +$6.68M 1.01% 14
2019
Q2 		$24.6M Buy
+2,187,614
New +$21.1M 0.77% 29
2014
Q3 		– Sell
-205,019
Closed -$980K – 547
2014
Q2 		$980K Sell
205,019
-19,379
-9% -$118K 0.03% 448
2014
Q1 		$2.13M Buy
+224,398
New +$2.03M 0.07% 323

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Driehaus Capital Management's CYTK Position: Q1 2024 in Review

Driehaus Capital Management sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 220,384 shares — an estimated $18.4M sold.

Driehaus Capital Management first reported a position in CYTK in Q1 2014 and held it in 19 quarters. The position peaked at $106M in Q4 2021. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Driehaus Capital Management reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 220,384 Cytokinetics shares in Q1 2024, an estimated $18.4M.
  • Driehaus Capital Management first reported a position in Cytokinetics in Q1 2014 and held it in 19 quarters.
  • Driehaus Capital Management's Cytokinetics position peaked at $106M in Q4 2021.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Driehaus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.